Bryostatin-1: a novel PKC inhibitor in clinical development

Related Experiment Video

Updated: Aug 3, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Jeremy Kortmansky1, Gary K Schwartz

  • 1Department of Medicine, Division of Solid Tumor Oncology, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

Cancer Investigation
|January 23, 2004
PubMed

Insights

Bryostatin-1, a novel marine compound, shows promise in cancer therapy by modulating protein kinase C (PKC). It inhibits tumor growth and enhances chemotherapy, with ongoing clinical trials yielding encouraging results.

Area of Science:

  • Oncology
  • Pharmacology
  • Marine Biotechnology

Background:

  • Protein kinase C (PKC) modulation is a novel cancer therapy strategy.
  • Bryostatin-1, a marine-derived macrocyclic lactone, interacts with the regulatory domain of PKC.
  • Bryostatin-1 exhibits biphasic effects on PKC: activation with short-term exposure and downregulation with prolonged exposure.

Purpose of the Study:

  • To investigate the therapeutic potential of Bryostatin-1 in cancer treatment.
  • To evaluate Bryostatin-1's effects on cancer cell proliferation, differentiation, and apoptosis.
  • To assess Bryostatin-1's synergistic effects with standard chemotherapy.

Main Methods:

  • Treatment of hematological and solid tumor cell lines with Bryostatin-1.
  • Preclinical studies evaluating combination therapy with Bryostatin-1 and chemotherapy.
  • Phase I and Phase II clinical trials assessing Bryostatin-1 efficacy and toxicity.

Main Results:

  • Bryostatin-1 inhibited proliferation, induced differentiation, and promoted apoptosis in various cancer cell lines.
  • Preclinical data demonstrated that Bryostatin-1 significantly potentiates chemotherapy effects, often in a sequence-specific manner.
  • Clinical trials reported minimal single-agent activity but encouraging results in combination with standard chemotherapy.

Conclusions:

  • Bryostatin-1 represents a promising novel approach to cancer therapy, particularly in combination regimens.
  • Further clinical investigation is warranted to optimize Bryostatin-1 combination therapies.
  • The observed toxicities (myalgias, nausea, vomiting) require careful management during treatment.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...